Compounds > n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine
Page last updated: 2024-09-03

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and chymostatin

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with chymostatin in 1 studies

Compound Research Comparison

Studies
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)		Trials
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)		Recent Studies (post-2010)
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)		Studies
(chymostatin)		Trials
(chymostatin)		Recent Studies (post-2010) (chymostatin)
79116167014

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kurita, Y; Nakao, H; Ogawa, H; Takamori, K; Tsuboi, R1

Other Studies

1 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and chymostatin

ArticleYear
Induction and inhibition of cathepsin B and hemoglobin-hydrolase activity in murine B16 melanoma by thiol protease inhibitors.
    Comparative biochemistry and physiology. B, Comparative biochemistry, 1986, Volume: 85, Issue:2

    Topics: Animals; Antipain; Cathepsin B; Kinetics; Leucine; Leupeptins; Melanoma, Experimental; Mice; Oligopeptides; Peptide Hydrolases; Protease Inhibitors

1986